MedTrace Logo

Increasing Uptake of Cascade Testing in Families With Familial Cancer Syndromes: A Randomized Controlled Trial of a Registry-aided Model.

NCT07626814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 545

Last updated 2026-06-04

No results posted yet for this study

Summary

The purpose of this study is to compare the uptake rates of a patient-initiated model of cascade testing with a registry-aided model amongst relatives of patients identified to have a particular cancer predisposition gene. Cascade testing allows the benefits of genetic testing to spread beyond the patient and enables other family members to make an informed choice on genetic testing. The researcher team hopes to study the rates of cascade testing using the two models, while concurrently comparing the adherence of identified carriers to risk management recommendations, including surveillance imaging and/or prophylactic surgeries. The team also aims to understand the willingness, acceptability and barriers of a registry-aided model.

Conditions

  • Hereditary Cancer Syndromes

Interventions

OTHER

Proband-dependent approach

Probands assigned to the control arm will be offered family letters to distribute to their at-risk relatives (ARRs). These family letters encourage relatives to see a general practitioner for a referral to genetic counselling and cascade testing.

OTHER

Combination of the proband-dependent approach with additional registry-aided testing reminders

Like the control arm, probands will be given the same family letters to distribute to their ARRs. In addition, a genetics coordinator will contact their first-degree relatives (FDRs) by phone/ email to inform them about genetic testing and advise them to obtain a referral from a general practitioner. The coordinator will remind relatives of their eligibility for genetic testing and assist them with queries at 1, 3, and 6 months after initial contact. Upon visiting for pre-test genetic counselling, FDRs will be further invited to provide contact details of other untested.

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Clin Asst Prof Chiang Jianbang, MBBS, MRCP (UK), MMed · National Cancer Centre, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2026-02-06
Completion
2026-02-06

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07626814 on ClinicalTrials.gov